Summary

Global Retinal Vein Occlusion Treatment Market was valued at USD 2.87 billion in 2024 and is expected to reach USD 4.26 billion by 2030 with a CAGR of 6.80% during the forecast period. The global retinal vein occlusion treatment market is a dynamic and rapidly evolving sector within the broader healthcare industry. Retinal vein occlusion (RVO) is a common vascular disorder of the eye that can lead to vision impairment if left untreated, making it a significant concern for both patients and healthcare professionals. As the aging population continues to grow worldwide, the prevalence of RVO is on the rise, driving the demand for innovative and effective treatment options.
Key factors influencing the global RVO treatment market include advancements in medical technology, increasing awareness among patients, and a surge in research and development activities. Pharmaceutical companies are actively engaged in the development of novel drugs and therapies to address RVO, with a focus on improving patient outcomes and quality of life. The market for RVO treatment encompasses various approaches, including pharmacological interventions, laser therapy, and surgical procedures. Anti-VEGF (vascular endothelial growth factor) drugs have gained prominence in recent years as an effective pharmacological treatment option, helping to reduce edema and improve vision in RVO patients. Additionally, laser therapy and surgical interventions are utilized in specific cases to manage complications or restore blood flow in the affected retinal veins.
Key Market Drivers
Growing Aging Population
The aging population is a significant factor contributing to the growth of the global retinal vein occlusion (RVO) treatment market. As the world's demographic landscape undergoes a profound shift, with a substantial increase in the elderly population, the incidence of age-related eye conditions, such as RVO, is on the rise. RVO is notably more prevalent in individuals over the age of 50, making it a condition closely associated with the aging process. This demographic shift is driving demand for effective RVO treatments and significantly impacting the market in several ways.
According to WHO, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.
Key Market Challenges
Limited Treatment Options
The global retinal vein occlusion (RVO) treatment market faces a significant hurdle in the form of limited treatment options, which is hindering its growth and effectiveness. RVO is a vascular eye disorder that can result in vision impairment, and while there have been notable advances in treatment options, there remains a substantial portion of patients for whom the available treatments may be insufficient. This limitation poses a major challenge, as it leaves a significant portion of RVO patients without optimal solutions for their condition.
At present, the primary pharmacological approach to RVO treatment involves anti-vascular endothelial growth factor (anti-VEGF) drugs, which have shown efficacy in addressing macular edema and inflammation. However, these treatments are not universally effective, and there is a considerable variation in patient responses. Some individuals may experience minimal or no improvement, while others may require ongoing treatment that can be burdensome and uncomfortable. The inability to offer personalized, effective treatment options for all RVO patients hinders the market's ability to meet the diverse needs of
Key Market Trends
Advancements in Pharmacological Treatments
Advancements in pharmacological treatments have played a pivotal role in boosting the global retinal vein occlusion (RVO) treatment market. RVO, a vascular eye disorder that can lead to vision impairment, has seen remarkable progress in the development of novel therapies, particularly in the form of anti-vascular endothelial growth factor (anti-VEGF) drugs. These advancements have significantly improved the landscape of RVO treatment, offering patients more effective and convenient options for managing the condition.
Anti-VEGF drugs, such as aflibercept and ranibizumab, have emerged as the cornerstone of RVO treatment, primarily addressing RVO-related macular edema. These drugs work by inhibiting the growth of abnormal blood vessels in the retina, reducing inflammation, and preventing the leakage of fluid into the macula. The introduction of anti-VEGF treatments has revolutionized RVO management, offering patients a less invasive and more patient-friendly therapeutic approach. They have proven effective in reducing edema, improving visual outcomes, and preserving the patient's quality of life.
Key Market Players
• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Regeneron Pharmaceuticals Inc.
• Taiwan Liposome Company, Ltd.
• Aerie Pharmaceuticals Inc.
• CalciMedica Inc.
• Outlook Therapeutics, Inc.
• Kodiak Sciences Inc.
• Chugai Pharmaceutical Co., Ltd.
• Pfizer Inc.
Report Scope:
In this report, the Global Retinal Vein Occlusion Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Retinal Vein Occlusion Treatment Market, By Disease Type:
o Central Retinal Vein Occlusion (CRVO)
o Branch Retinal Vein Occlusion (BRVO)
• Retinal Vein Occlusion Treatment Market, By Treatment:
o Anti-vascular Endothelial Growth Factor (Anti-VEGF)
o Corticosteroid Drugs
o Others
• Retinal Vein Occlusion Treatment Market, By End-user:
o Fully Automated
o Semi-Automated
o Manual
• Retinal Vein Occlusion Treatment Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Retinal Vein Occlusion Treatment Market.
Available Customizations:
Global Retinal Vein Occlusion Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Retinal Vein Occlusion Treatment Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Disease Type (Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO))
4.2.2. By Treatment (Anti-vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, Others)
4.2.3. By End-user (Hospital & Clinics, Retail Pharmacy, Others)
4.2.4. By Region
4.2.5. By Company (2024)
4.3. Market Map
4.3.1. By Disease Type
4.3.2. By Treatment
4.3.3. By End-user
4.3.4. By Region
5. Asia Pacific Retinal Vein Occlusion Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease Type
5.2.2. By Treatment
5.2.3. By End-user
5.2.4. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Retinal Vein Occlusion Treatment Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Disease Type
5.3.1.2.2. By Treatment
5.3.1.2.3. By End-user
5.3.2. India Retinal Vein Occlusion Treatment Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Disease Type
5.3.2.2.2. By Treatment
5.3.2.2.3. By End-user
5.3.3. Australia Retinal Vein Occlusion Treatment Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Disease Type
5.3.3.2.2. By Treatment
5.3.3.2.3. By End-user
5.3.4. Japan Retinal Vein Occlusion Treatment Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Disease Type
5.3.4.2.2. By Treatment
5.3.4.2.3. By End-user
5.3.5. South Korea Retinal Vein Occlusion Treatment Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Disease Type
5.3.5.2.2. By Treatment
5.3.5.2.3. By End-user
6. Europe Retinal Vein Occlusion Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease Type
6.2.2. By Treatment
6.2.3. By End-user
6.2.4. By Country
6.3. Europe: Country Analysis
6.3.1. France Retinal Vein Occlusion Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease Type
6.3.1.2.2. By Treatment
6.3.1.2.3. By End-user
6.3.2. Germany Retinal Vein Occlusion Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease Type
6.3.2.2.2. By Treatment
6.3.2.2.3. By End-user
6.3.3. Spain Retinal Vein Occlusion Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease Type
6.3.3.2.2. By Treatment
6.3.3.2.3. By End-user
6.3.4. Italy Retinal Vein Occlusion Treatment Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Disease Type
6.3.4.2.2. By Treatment
6.3.4.2.3. By End-user
6.3.5. United Kingdom Retinal Vein Occlusion Treatment Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Disease Type
6.3.5.2.2. By Treatment
6.3.5.2.3. By End-user
7. North America Retinal Vein Occlusion Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease Type
7.2.2. By Treatment
7.2.3. By End-user
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Retinal Vein Occlusion Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease Type
7.3.1.2.2. By Treatment
7.3.1.2.3. By End-user
7.3.2. Mexico Retinal Vein Occlusion Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease Type
7.3.2.2.2. By Treatment
7.3.2.2.3. By End-user
7.3.3. Canada Retinal Vein Occlusion Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease Type
7.3.3.2.2. By Treatment
7.3.3.2.3. By End-user
8. South America Retinal Vein Occlusion Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease Type
8.2.2. By Treatment
8.2.3. By End-user
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Retinal Vein Occlusion Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease Type
8.3.1.2.2. By Treatment
8.3.1.2.3. By End-user
8.3.2. Argentina Retinal Vein Occlusion Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease Type
8.3.2.2.2. By Treatment
8.3.2.2.3. By End-user
8.3.3. Colombia Retinal Vein Occlusion Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease Type
8.3.3.2.2. By Treatment
8.3.3.2.3. By End-user
9. Middle East and Africa Retinal Vein Occlusion Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease Type
9.2.2. By Treatment
9.2.3. By End-user
9.2.4. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Retinal Vein Occlusion Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease Type
9.3.1.2.2. By Treatment
9.3.1.2.3. By End-user
9.3.2. Saudi Arabia Retinal Vein Occlusion Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease Type
9.3.2.2.2. By Treatment
9.3.2.2.3. By End-user
9.3.3. UAE Retinal Vein Occlusion Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease Type
9.3.3.2.2. By Treatment
9.3.3.2.3. By End-user
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Retinal Vein Occlusion Treatment Market: SWOT Analysis
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. Competitive Landscape
14.1. AbbVie Inc.
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Current Capacity Analysis
14.1.5. Financials (In case of listed)
14.1.6. Recent Developments
14.1.7. SWOT Analysis
14.2. F. Hoffmann-La Roche Ltd.
14.3. Regeneron Pharmaceuticals Inc.
14.4. Taiwan Liposome Company, Ltd.
14.5. Aerie Pharmaceuticals Inc.
14.6. CalciMedica Inc.
14.7. Outlook Therapeutics, Inc.
14.8. Kodiak Sciences Inc.
14.9. Chugai Pharmaceutical Co., Ltd.
14.10.Pfizer Inc.
15. Strategic Recommendations
16. About Us & Disclaimer